Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 8/20 | 0.53 |
| ▸ | PTGER3 | P43115 | 8/20 | 0.53 |
| ▸ | PTGER1 | P34995 | 7/20 | 0.53 |
| ▸ | PTGER2 | P43116 | 7/20 | 0.53 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | MME | P08473 | 1/20 | 0.46 |
| ▸ | RXRA | P19793 | 2/20 | 0.46 |
| ▸ | RXRB | P28702 | 2/20 | 0.46 |
| ▸ | RXRG | P48443 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2534013 | 0.89 | FFAR1 (0.56) | PTGER4PTGER3PTGER1PTGER2FFAR4 | |
| SCHEMBL2535066 | 0.85 | FFAR4 (0.49) | PTGER4PTGER3PTGER1PTGER2FFAR4 | |
| SCHEMBL2536390 | 0.85 | FFAR4 (0.49) | PTGER4PTGER3PTGER1PTGER2FFAR4 | |
| SCHEMBL2538185 | 0.85 | NPSR1 (0.49) | PTGER4PTGER3PTGER1PTGER2FFAR4 | |
| SCHEMBL2540490 | 0.85 | FFAR4 (0.48) | PTGER4PTGER3PTGER1PTGER2FFAR4 | |
| SCHEMBL2534023 | 0.85 | PTGER4 (0.55) | PTGER4PTGER3PTGER1PTGER2FFAR4 | |
| SCHEMBL2531052 | 0.84 | PTGER4 (0.58) | PTGER4PTGER3PTGER1PTGER2FFAR4 | |
| SCHEMBL2536062 | 0.84 | RXRA (0.53) | PTGER4PTGER3PTGER1PTGER2FFAR4 | |
| SCHEMBL2541443 | 0.83 | FFAR4 (0.53) | PTGER4PTGER3PTGER1PTGER2FFAR4 | |
| SCHEMBL2533427 | 0.83 | FFAR4 (0.51) | PTGER4PTGER3PTGER1PTGER2FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8044236-B2 | Inhibitors against plasminogen activator inhibitor-1 (PAI-1); anticoagulants; 2-(aryl or aralkyloxy-)-5-(aryl)phenyl}acetic acid (or derivatives of propionic acid, propenoic acid, N-oxamic acid or 1H-tetrazol-5-yl); occlusion, stenosis; low molecular weight; gene expression inhibition | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2011-10-25 | — | — | US | disclosed |
| EP-2080751-A1 | CARBOXYLIC ACID DERIVATIVE | Institute of Medicinal Molecular Design, Inc. (JP) | 2009-07-22 | — | — | EP | disclosed |
| US-20080275116-A1 | Carboxilic acid derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275116-A1 | Carboxilic acid derivatives | SERPINE1, CTRL, SERPINC1 | PTGER4 3046/4885PTGER3 2505/4885PTGER1 905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.